0000000000752569

AUTHOR

Raffaele Griffo

showing 4 related works from this author

ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiova…

2017

Atherosclerotic cardiovascular disease still represents the leading cause of death in western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proven effective in improving clinical outcomes. This document is focused on the clinical management of hypercholesterolemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors have considered with particular attention the role of hypercholesterole…

medicine.medical_specialtySettore MED/09 - Medicina InternaPCSK9 inhibitorMEDLINE030204 cardiovascular system & hematologyNOatherosclerosis; diagnostic and therapeutic pathways; hypercholesterolaemia; PCSK9 inhibitors; statins; sustainable health careDiagnostic and therapeutic pathways03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicine030212 general & internal medicineIntensive care medicineRisk managementCause of deathHypercholesterolaemiabusiness.industryAtherosclerotic cardiovascular diseaseCholesterolSustainable health careStatinsDiagnostic and therapeutic pathwayStatinHigh Cholesterol LevelsArticlesmedicine.diseaseAtherosclerosischemistryPCSK9 inhibitorsAtherosclerosiCardiologylipids (amino acids peptides and proteins)Atherosclerosis; Diagnostic and therapeutic pathways; Hypercholesterolaemia; PCSK9 inhibitors; Statins; Sustainable health care; Cardiology and Cardiovascular MedicineCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal Supplements : Journal of the European Society of Cardiology
researchProduct

Cardiopulmonary exercise testing in COVID-19 patients at 3 months follow-up

2021

Abstract Background Long-term effects of Coronavirus Disease of 2019 (COVID-19) and their sustainability are of the utmost relevance. For the chronic phase, the main concerns are the development of pulmonary interstitial disease and/or lingering cardiovascular involvement. How to intercept, assess, and treat these patients with long-term consequences of COVID-19 remains uncertain. Purpose We aimed to determine: 1) functional capacity of COVID-19 survivors by cardiopulmonary exercise testing (CPET); 2) those characteristics associated with CPET performance; 3) safety and tolerability of CPET. Methods We prospectively enrolled consecutive patients with laboratory-confirmed COVID-19 discharged…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industryPhysical therapymedicineCardiopulmonary exercise testingAcademicSubjects/MED00200Cardiology and Cardiovascular MedicinebusinessExercise TestingAbstract SupplementEuropean Heart Journal
researchProduct

Cardiopulmonary exercise testing in COVID-19 patients at 3 months follow-up☆

2021

Abstract Background Long-term effects of Coronavirus Disease of 2019 (COVID-19) are of utmost relevance. We aimed to determine: 1) the functional capacity of COVID-19 survivors by cardiopulmonary exercise testing (CPET); 2) the characteristics associated with cardiopulmonary exercise testing (CPET) performance; 3) the safety and tolerability of CPET. Methods We prospectively enrolled consecutive patients with laboratory-confirmed COVID-19 from Azienda Sanitaria Locale 3, Genoa. Three months after hospital discharge a complete clinical evaluation, trans-thoracic echocardiography, CPET, pulmonary function tests, and dominant leg extension (DLE) maximal strength measurement were performed. Res…

medicine.medical_specialtymedicine.medical_treatmentBacterial ToxinsArticlePulmonary function testingCardiopulmonary exercise testing; Coronavirus; Coronavirus infection; COVID-19; Lung diseases; Severe acute respiratory syndrome; Echocardiography; Exercise Tolerance; Follow-Up Studies; Humans; Oxygen Consumption; SARS-CoV-2; COVID-19; Exercise TestOxygen ConsumptionInternal medicineDiffusing capacityCoronavirus infectionMedicineHumansSurvivorsAdverse effectLung diseasesRehabilitationExercise Tolerancebusiness.industrySARS-CoV-2VO2 maxCOVID-19Cardiopulmonary exercise testingCoronavirusTolerabilitySevere acute respiratory syndromeEchocardiographyCohortExercise TestCardiology and Cardiovascular MedicinebusinessAnaerobic exerciseFollow-Up StudiesInternational Journal of Cardiology
researchProduct

Documento di consenso intersocietario ANMCO/ISS/AMD/ANCE/ARCA/FADOI/ GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/ SID/SIF/SIMEU/SIMG/SIMI/SISA Colesterolo …

2016

Atherosclerotic cardiovascular disease still represents the leading cause of death in western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proven effective in improving clinical outcomes. This document is focused on the clinical management of hypercholesterolemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors have considered with particular attention the role of hypercholesterole…

Settore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaSettore MED/09 - Medicina InternaItalyCardiovascular DiseaseRisk FactorAnticholesteremic AgentHypercholesterolemiaSettore BIO/14 - FarmacologiaConsensuCardiology and Cardiovascular MedicineSettore MED/11 - Malattie Dell'Apparato CardiovascolareHuman
researchProduct